Achillion Pharmaceuticals Company Profile (NASDAQ:ACHN)

About Achillion Pharmaceuticals

Achillion Pharmaceuticals logoAchillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on its complement inhibitor platform, directed at advancing small molecule compounds that have the potential to be used in the treatment of immune-related diseases associated with the complement system. The complement system is part of the body's immune system. The Company has initiated a first-in-human Phase I clinical trial for its first complement factor D inhibitor, ACH-4471, to assess safety, tolerability, pharmacokinetics, or PK, and pharmacodynamics, or PD. The Company has developed a portfolio of drug candidates, including odalasvir, ACH-3422 and sovaprevir.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: ACHN
  • CUSIP: 00448Q20
Key Metrics:
  • Previous Close: $4.24
  • 50 Day Moving Average: $4.26
  • 200 Day Moving Average: $5.93
  • 52-Week Range: $3.78 - $10.06
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -10.60
  • P/E Growth: -0.42
  • Market Cap: $579.52M
  • Outstanding Shares: 136,680,000
  • Beta: 1.59
Profitability:
  • Return on Equity: -9.46%
  • Return on Assets: -9.16%
Debt:
  • Current Ratio: 29.93%
  • Quick Ratio: 29.93%
Additional Links:
Companies Related to Achillion Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Achillion Pharmaceuticals (NASDAQ:ACHN) (?)
Ratings Breakdown: 3 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $10.50 (147.64% upside)

Analysts' Ratings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Show:
DateFirmActionRatingPrice TargetDetails
2/2/2017Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$10.00View Rating Details
11/6/2016Robert W. BairdReiterated RatingOutperform$10.00View Rating Details
11/4/2016Chardan CapitalUpgradeSell -> Neutral$5.00View Rating Details
11/3/2016WedbushReiterated RatingOutperform$13.00View Rating Details
11/3/2016Leerink SwannReiterated RatingMarket PerformView Rating Details
9/26/2016Jefferies Group LLCReiterated RatingHoldView Rating Details
9/15/2016FBR & CoInitiated CoverageOutperform$16.00View Rating Details
7/7/2016JMP SecuritiesUpgradeMarket Perform -> Outperform$13.00View Rating Details
2/25/2016Maxim GroupReiterated RatingBuy$11.00 -> $8.00View Rating Details
12/8/2015William BlairReiterated RatingOutperform$16.00View Rating Details
5/23/2015Cowen and CompanyReiterated RatingOutperformView Rating Details
4/6/2015Deutsche Bank AGReiterated RatingBuy$25.00 -> $20.00View Rating Details
3/4/2015Barclays PLCInitiated CoverageUnderweight$8.00View Rating Details
(Data available from 2/23/2015 forward)

Earnings

Earnings History for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
2/23/2017Q4 2016($0.18)($0.03)$15.00 millionViewN/AView Earnings Details
11/3/2016Q3($0.16)($0.15)ViewN/AView Earnings Details
8/4/2016Q2($0.15)($0.14)ViewN/AView Earnings Details
5/3/2016Q116($0.14)($0.13)ViewN/AView Earnings Details
2/25/2016Q4$0.09$0.12$31.40 million$31.60 millionViewN/AView Earnings Details
11/5/2015Q3$0.09$0.19$32.62 million$33.82 millionViewN/AView Earnings Details
8/10/2015Q2($0.18)($0.25)$0.71 millionViewN/AView Earnings Details
5/7/2015Q115($0.22)($0.17)ViewN/AView Earnings Details
3/5/2015Q414($0.18)($0.21)ViewN/AView Earnings Details
11/4/2014Q314($0.18)($0.16)ViewN/AView Earnings Details
8/7/2014Q214($0.18)($0.16)ViewN/AView Earnings Details
5/7/2014Q114($0.16)($0.17)ViewN/AView Earnings Details
3/7/2014Q413($0.16)($0.14)$0.01 millionViewN/AView Earnings Details
11/12/2013Q3($0.20)($0.14)ViewN/AView Earnings Details
5/7/2013Q113($0.15)($0.14)ViewN/AView Earnings Details
11/8/2012Q312($0.17)($0.20)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Achillion Pharmaceuticals (NASDAQ:ACHN)
Current Year EPS Consensus Estimate: $-0.58 EPS
Next Year EPS Consensus Estimate: $-0.40 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20163($0.16)($0.16)($0.16)
Q3 20162($0.19)($0.15)($0.17)
Q4 20165($0.19)($0.15)($0.17)
Q1 20171($0.17)($0.17)($0.17)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Achillion Pharmaceuticals (NASDAQ:ACHN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Achillion Pharmaceuticals (NASDAQ:ACHN)
Insider Ownership Percentage: 6.52%
Institutional Ownership Percentage: 77.85%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/22/2016Jason S FishermanDirectorBuy10,000$3.96$39,600.00View SEC Filing  
12/5/2016Mary Kay FentonCFOBuy2,500$4.11$10,275.00View SEC Filing  
12/2/2016Joel C BarrishInsiderBuy2,500$4.06$10,150.00View SEC Filing  
12/30/2015David ApelianinsiderSell10,000$10.50$105,000.00View SEC Filing  
12/28/2015Mary Kay FentonCFOSell43,500$10.08$438,480.00View SEC Filing  
11/11/2015Nicole VitulloDirectorSell550,000$10.17$5,593,500.00View SEC Filing  
9/25/2015Nicole VitulloDirectorSell9,310$8.22$76,528.20View SEC Filing  
1/23/2015Mary Kay FentonCFOSell13,125$16.00$210,000.00View SEC Filing  
1/21/2015Milind DeshpandeCEOSell100,000$15.00$1,500,000.00View SEC Filing  
9/30/2014Ra Capital Management, LlcInsiderSell1,332,014$10.20$13,586,542.80View SEC Filing  
9/29/2014Ra Capital Management, LlcInsiderSell221,014$10.96$2,422,313.44View SEC Filing  
9/26/2014Ra Capital Management, LlcMajor ShareholderSell2,372,915$11.17$26,505,460.55View SEC Filing  
9/25/2014Ra Capital Management, LlcMajor ShareholderSell497,986$11.05$5,502,745.30View SEC Filing  
9/24/2014Ra Capital Management, LlcMajor ShareholderSell1,204,929$11.27$13,579,549.83View SEC Filing  
9/23/2014Ra Capital Management, LlcMajor ShareholderSell2,595,071$11.29$29,298,351.59View SEC Filing  
9/2/2014Ra Capital Management, LlcMajor ShareholderSell835,293$11.63$9,714,457.59View SEC Filing  
8/27/2014Ra Capital Management, LlcMajor ShareholderSell2,711,352$11.33$30,719,618.16View SEC Filing  
8/26/2014Ra Capital Management, LlcMajor ShareholderSell2,112,867$11.35$23,981,040.45View SEC Filing  
8/25/2014Joseph TruittEVPSell25,000$10.82$270,500.00View SEC Filing  
8/25/2014Ra Capital Management, LlcMajor ShareholderSell331,396$10.96$3,632,100.16View SEC Filing  
8/18/2014Milind DeshpandeCEOSell216,624$10.00$2,166,240.00View SEC Filing  
8/18/2014Ra Capital Management, LlcMajor ShareholderSell4,235,000$9.53$40,359,550.00View SEC Filing  
8/15/2014Michael D KishbauchDirectorSell495,812$9.40$4,660,632.80View SEC Filing  
8/13/2014Gary E FrashierDirectorSell5,000$8.00$40,000.00View SEC Filing  
6/20/2014Ra Capital Management, LlcInsiderSell880,000$8.40$7,392,000.00View SEC Filing  
6/16/2014Gary E FrashierDirectorSell55,000$8.00$440,000.00View SEC Filing  
6/16/2014Joseph TruittEVPSell25,000$7.82$195,500.00View SEC Filing  
6/16/2014Qvt Associates Gp LlcMajor ShareholderSell1,819,551$7.70$14,010,542.70View SEC Filing  
6/11/2014Qvt Associates Gp LlcMajor ShareholderSell128,649$7.66$985,451.34View SEC Filing  
6/10/2014Joseph TruittEVPSell50,000$6.02$301,000.00View SEC Filing  
6/10/2014Michael D KishbauchDirectorSell371,937$7.75$2,882,511.75View SEC Filing  
12/30/2013Qvt Associates Gp Llcmajor shareholderSell170,239$3.34$568,598.26View SEC Filing  
12/26/2013Qvt Associates Gp Llcmajor shareholderSell121,205$3.44$416,945.20View SEC Filing  
12/23/2013Qvt Associates Gp Llcmajor shareholderSell289,141$3.24$936,816.84View SEC Filing  
12/19/2013Qvt Associates Gp Llcmajor shareholderSell222,612$3.09$687,871.08View SEC Filing  
12/17/2013Qvt Associates Gp Llcmajor shareholderSell92,803$3.11$288,617.33View SEC Filing  
11/22/2013Dennis LiottaDirectorBuy10,000$2.98$29,800.00View SEC Filing  
11/20/2013Ra Capital Management, LlcInsiderBuy1,110,000$2.55$2,830,500.00View SEC Filing  
11/19/2013Jason FishermanDirectorBuy15,000$2.63$39,450.00View SEC Filing  
11/12/2013Ra Capital Management, LlcInsiderBuy1,795,000$2.48$4,451,600.00View SEC Filing  
10/31/2013Ra Capital Management, LlcInsiderBuy1,186,007$2.45$2,905,717.15View SEC Filing  
10/14/2013Ra Capital Management, LlcInsiderBuy2,369,229$2.79$6,610,148.91View SEC Filing  
10/11/2013Ra Capital Management, LlcInsiderBuy2,448,710$2.56$6,268,697.60View SEC Filing  
9/30/2013Ra Capital Management, LlcInsiderBuy2,800,000$2.98$8,344,000.00View SEC Filing  
8/14/2013Jason FishermanDirectorBuy5,000$6.83$34,150.00View SEC Filing  
8/12/2013Dennis LiottaDirectorBuy5,000$6.47$32,350.00View SEC Filing  
8/9/2013Qvt Associates Gp Llcmajor shareholderBuy102,282$6.41$655,627.62View SEC Filing  
7/11/2013Qvt Associates Gp LlcMajor ShareholderBuy401,017$6.46$2,590,569.82View SEC Filing  
7/10/2013Qvt Associates Gp LlcMajor ShareholderBuy390,944$6.33$2,474,675.52View SEC Filing  
7/8/2013Qvt Associates Gp LlcMajor ShareholderBuy642,509$6.28$4,034,956.52View SEC Filing  
7/3/2013Qvt Associates Gp LlcMajor ShareholderBuy1,963,248$6.43$12,623,684.64View SEC Filing  
7/1/2013Gary E FrashierDirectorSell5,000$8.17$40,850.00View SEC Filing  
6/21/2013Jason S FishermanDirectorBuy10,000$7.63$76,300.00View SEC Filing  
6/7/2013Gary E FrashierDirectorSell5,000$8.37$41,850.00View SEC Filing  
6/3/2013Jason S FishermanDirectorBuy10,000$7.87$78,700.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Achillion Pharmaceuticals (NASDAQ:ACHN)
DateHeadline
4-traders.com logoAchillion Pharmaceuticals : reports 4Q loss (NASDAQ:ACHN)
www.4-traders.com - February 23 at 8:20 PM
marketexclusive.com logoAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Files An 8-K Results of Operations and Financial Condition (NASDAQ:ACHN)
marketexclusive.com - February 23 at 8:20 PM
us.rd.yahoo.com logoAchillion Reports 2016 Fourth Quarter and Year-End Financial Results (NASDAQ:ACHN)
us.rd.yahoo.com - February 23 at 8:20 PM
us.rd.yahoo.com logo4:10 pm Achillion Pharma beats by $0.17, beats on revs; guides FY17 EPS below consensus (NASDAQ:ACHN)
us.rd.yahoo.com - February 23 at 8:20 PM
biz.yahoo.com logoACHILLION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report (NASDAQ:ACHN)
us.rd.yahoo.com - February 23 at 8:20 PM
biz.yahoo.com logoACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements (NASDAQ:ACHN)
us.rd.yahoo.com - February 23 at 8:20 PM
sg.finance.yahoo.com logoAchillion reports 4Q loss (NASDAQ:ACHN)
sg.finance.yahoo.com - February 23 at 8:20 PM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Growth & Stock Target in Focus - Winfield Review (NASDAQ:ACHN)
winfieldreview.com - February 23 at 3:18 PM
News IconFiscal Year Earnings Estimate on Achillion Pharmaceuticals, Inc.(ACHN) - Money Flow Index & Trends (NASDAQ:ACHN)
www.moneyflowtrends.com - February 23 at 3:18 PM
News IconTrading Watch: Checking in on Shares of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - BVN (NASDAQ:ACHN)
bvnewsjournal.com - February 22 at 3:16 PM
News IconMarket Check: Focusing on These Shares: Achillion Pharmaceuticals Inc (ACHN) - Rives Journal (NASDAQ:ACHN)
rivesjournal.com - February 22 at 3:16 PM
finance.yahoo.com logoBiotech's Rally Continues to Build in 2017: Today's Reports on Achillion Pharmaceuticals and Pulmatrix (NASDAQ:ACHN)
finance.yahoo.com - February 22 at 11:46 AM
News IconTechnical Trading: Focus on Shares of Achillion Pharmaceuticals Inc (ACHN) - Davidson Register (NASDAQ:ACHN)
davidsonregister.com - February 21 at 3:34 PM
News IconThe Charts Expose On Achillion Pharmaceuticals, Inc. (ACHN) Is Causing A Stir - NY Stock News (NASDAQ:ACHN)
nystocknews.com - February 21 at 3:34 PM
News IconStock Price of Achillion Pharmaceuticals, Inc. (ACHN) Decreases ... - Highland Mirror (NASDAQ:ACHN)
www.highlandmirror.com - February 21 at 3:34 PM
finance.yahoo.com logoAchillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:ACHN)
finance.yahoo.com - February 21 at 5:33 AM
News IconAnalysts Are Sizing Up Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Where Does the Sell-Side See It Going? - Winfield Review (NASDAQ:ACHN)
winfieldreview.com - February 20 at 5:25 AM
News IconImportant Analyst Assessments of Two Stocks: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN), Duke Realty ... - OracleTimes (NASDAQ:ACHN)
oracletimes.com - February 16 at 3:19 PM
istreetwire.com logoEquities Trend Analysis: HollyFrontier Corporation (HFC), Achillion ... - iStreetWire (NASDAQ:ACHN)
istreetwire.com - February 16 at 3:19 PM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Bending Lower, Touching Top Loser's List - Aiken Advocate (NASDAQ:ACHN)
aikenadvocate.com - February 16 at 3:19 PM
News IconPeeling Back The Layers on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Analysts & Street Weigh In - Winfield Review (NASDAQ:ACHN)
winfieldreview.com - February 15 at 1:36 AM
News IconConsensus Estimates on Earnings & Stock Price in Focus for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Shares - Aiken Advocate (NASDAQ:ACHN)
aikenadvocate.com - February 14 at 8:34 PM
News IconLooking at the Levels for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Rives Journal (NASDAQ:ACHN)
rivesjournal.com - February 14 at 8:34 PM
News IconStreet Analysts Take Aim at Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Rockville Register (NASDAQ:ACHN)
rockvilleregister.com - February 14 at 8:34 PM
News IconChecking in on Signals for Achillion Pharmaceuticals Inc. (ACHN) - BVN (NASDAQ:ACHN)
bvnewsjournal.com - February 14 at 3:31 PM
News IconInsider Alert: Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Notable Insider Activity - Winfield Review (NASDAQ:ACHN)
winfieldreview.com - February 13 at 8:25 PM
News IconMarket Scanner: Checking the Levels for Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - The Standard (NASDAQ:ACHN)
6milestandard.com - February 13 at 3:22 PM
News IconTale of the Tape: Technical Recap for Achillion Pharmaceuticals Inc. (ACHN) - Baldwin Journal (NASDAQ:ACHN)
baldwinjournal.com - February 13 at 3:22 PM
globenewswire.com logoAchillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference - GlobeNewswire (press release) (NASDAQ:ACHN)
globenewswire.com - February 13 at 3:22 PM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analyst Estimates & Target Update - Aiken Advocate (NASDAQ:ACHN)
aikenadvocate.com - February 11 at 3:17 PM
News IconTrading Focus: Eye on Shares of Achillion Pharmaceuticals Inc. (ACHN) - Rives Journal (NASDAQ:ACHN)
rivesjournal.com - February 10 at 1:19 AM
News IconNews Impact Score Of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) At 81 - Stock Observer (NASDAQ:ACHN)
www.thestockobserver.com - February 9 at 3:17 PM
istreetwire.com logoMomentum Stocks: Swift Transportation Company (SWFT), Achillion Pharmaceuticals, Inc. (ACHN), Civeo Corporation ... - iStreetWire (NASDAQ:ACHN)
istreetwire.com - February 6 at 3:21 PM
istreetwire.com logoStocks Trend Analysis: WisdomTree Investments, Inc. (WETF ... - iStreetWire (NASDAQ:ACHN)
istreetwire.com - February 3 at 3:23 PM
capitalcube.com logoAchillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US : February 3, 2017 (NASDAQ:ACHN)
www.capitalcube.com - February 3 at 3:23 PM
marketexclusive.com logoAnalyst Activity – Ladenburg Thalmann Financial Services Initiates Coverage On Achillion Pharmaceuticals (NASDAQ ... - Market Exclusive (NASDAQ:ACHN)
marketexclusive.com - February 2 at 3:18 PM
finance.yahoo.com logoCoverage initiated on Achillion Pharma by Ladenburg Thalmann (NASDAQ:ACHN)
finance.yahoo.com - February 2 at 3:17 PM
thestreet.com logoPremarket Biotech Movers: Cytokinetics, Achillion, Qiagen (NASDAQ:ACHN)
www.thestreet.com - February 2 at 3:17 PM
News IconAnalysts Are Circling Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): What is the Consensus' Take? - Wall Street Beacon (NASDAQ:ACHN)
wsbeacon.com - February 1 at 8:24 PM
News IconEarnings Snapshot & Analysts Target Update on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)? - Wall Street Beacon (NASDAQ:ACHN)
wsbeacon.com - February 1 at 3:21 PM
News IconEarnings Parade Rolls On, What Are Analysts Saying About Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)? - Wall Street Beacon (NASDAQ:ACHN)
wsbeacon.com - January 31 at 3:20 PM
News IconPeeling Back The Layers on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN): Analysts & Street Weigh In - Wall Street Beacon (NASDAQ:ACHN)
wsbeacon.com - January 30 at 8:29 PM
News IconAre Insiders Bumping Up Their Positions in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Wall Street Beacon (NASDAQ:ACHN)
wsbeacon.com - January 30 at 3:28 PM
News IconIs There Inherent Value in Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)? Analysts Delve Into The Stock - Wall Street Beacon (NASDAQ:ACHN)
wsbeacon.com - January 28 at 3:18 PM
News IconAnalyst Stock Trading Analysis on Achillion Pharmaceuticals, Inc. (ACHN) - Highland Mirror (NASDAQ:ACHN)
www.highlandmirror.com - January 27 at 3:35 PM
News IconTrading Spotlight: Zooming in on Shares of Achillion Pharmaceuticals Inc. (ACHN) - Sherwood Daily (NASDAQ:ACHN)
sherwooddaily.com - January 26 at 8:31 PM
News IconAnalysts Peering Into Their Crystal Balls, What's the Sentiment on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) - Wall Street Beacon (NASDAQ:ACHN)
wsbeacon.com - January 26 at 8:31 PM
News IconAchillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Analytical Report - The Newburgh Press (NASDAQ:ACHN)
newburghpress.com - January 26 at 3:30 PM
News IconNews Impact Score Of Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) At 93 - Stock Observer (NASDAQ:ACHN)
www.thestockobserver.com - January 26 at 3:30 PM
News IconStock Target Review on Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) Shares - Aiken Advocate (NASDAQ:ACHN)
aikenadvocate.com - January 25 at 8:24 PM

Social

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

Where is Achillion Pharmaceuticals' stock going? Where will Achillion Pharmaceuticals' stock price be in 2017?

9 equities research analysts have issued 12 month price targets for Achillion Pharmaceuticals' stock. Their predictions range from $5.00 to $16.00. On average, they anticipate Achillion Pharmaceuticals' stock price to reach $10.50 in the next year.

When will Achillion Pharmaceuticals announce their earnings?

Achillion Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

Who owns Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Orbimed Advisors LLC (9.59%), State Street Corp (3.75%), Janus Capital Management LLC (3.41%), Numeric Investors LLC (1.99%), FMR LLC (1.11%) and Renaissance Technologies LLC (0.69%). Company insiders that own Achillion Pharmaceuticals stock include David Apelian, Jason S Fisherman, Joel C Barrish, Mary Kay Fenton and Nicole Vitullo.

Who sold Achillion Pharmaceuticals stock? Who is selling Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, FMR LLC, Janus Capital Management LLC, Turner Investments LLC, Oxford Asset Management and Metropolitan Life Insurance Co. NY.

Who bought Achillion Pharmaceuticals stock? Who is buying Achillion Pharmaceuticals stock?

Achillion Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Numeric Investors LLC, State Street Corp, Renaissance Technologies LLC, Bogle Investment Management L P DE, Dimensional Fund Advisors LP, Two Sigma Investments LP, GSA Capital Partners LLP and Tudor Investment Corp Et Al. Company insiders that have bought Achillion Pharmaceuticals stock in the last two years include Jason S Fisherman, Joel C Barrish and Mary Kay Fenton.

How do I buy Achillion Pharmaceuticals stock?

Shares of Achillion Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Achillion Pharmaceuticals stock cost?

One share of Achillion Pharmaceuticals stock can currently be purchased for approximately $4.24.

Achillion Pharmaceuticals (NASDAQ:ACHN) Chart for Thursday, February, 23, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Earnings History Chart

Earnings by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Dividend History Chart

Dividend Payments by Quarter for Achillion Pharmaceuticals (NASDAQ:ACHN)

Last Updated on 2/23/2017 by MarketBeat.com Staff